18

Jan 2019

Aurobindo Pharma’s subsidiary Acrotech Biopharma to acquire portfolio of seven marketed oncology injectable products from Spectrum Pharmaceuticals

Acquisition for an upfront purchase price of $160 million in cash plus up to $140 million on achieving regulatory and sales-based milestones Acquired portfolio includes seven branded oncology injectable products which are currently being marketed. The acquisition also brings-in an experienced branded commercial infrastructure in the US The portfolio is expected to generate a revenue... Read more

06

Sep 2018

Aurobindo to acquire dermatology and oral solids businesses for Sandoz Inc., USA

Aurobindo to acquire dermatology and oral solids businesses from Sandoz Inc., USA Acquisition for an upfront purchase price of $0.9 billion in cash including potential upside in near term earn-out and additional potential earn-out on pipeline product in outer years. Aurobindo would become the 2nd largest generic player in the US by number of prescriptions Aurobindo... Read more

02

Jan 2018

Aurobindo Pharma USA receives the Community Enhancement Award from East Windsor Township!

It is an East Windsor Township tradition to recognize businesses – how important they are to the community, how proud the township is of them and how they contribute to the community – every year, Mayor Janice Mironov said There are three awards – the Business Beautification Award, the Community Service Award and the Community... Read more

15

Dec 2017

Aurobindo aims at cancer as it climbs the value chain

Developing and filing for both small-molecule and biological cancer therapies forms a key part of Aurobindo’s strategy to target higher-value products. Aidan Fry examines the company’s plan in this Generic’s bulletin Dec 2017 article.... Read more

30

Oct 2017

Aurobindo wins Company of the Year, Asia-Pacific Award at the Global Generics & Biosimilars Awards 2017

Frankfurt, 24 October 2017 – Aurobindo Pharma Limited and Generics Bulletin are pleased to announce that Aurobindo has won the Company of the Year, Asia-Pacific Award at the Global Generics & Biosimilars Awards 2017, organized by Generics Bulletin. The Company of the Year, Asia-Pacific Award was sponsored by Eva Pharma and judged by an expert panel. “Congratulations... Read more

08

Aug 2017

Aurobindo Receives FDA Approval for the line of OC tablets Aurovela™

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Aurovela™ line of OC tablets. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Aurovela™ to be bioequivalent and, therefore, therapeutically equivalent to Loestrin® line of oral contraceptive products. Please see table below for each of... Read more

12

Jun 2017

Aurobindo Pharma looks to sell cancer drugs in the US by year end

Hyderabad-based pharma major says US FDA approval likely to come after upcoming audit Hyderabad-based Aurobindo Pharma Limited is hoping to receive three-four product approvals in the oncology space from the US Food and Drug Administration (US FDA) before March 2018. The company’s optimistic prediction about a possible good start in this high-margin product business comes... Read more

19

Apr 2017

Veto Maryland House Bill 631!

Don’t Harm Patient Access to Affordable Generic Medicines by Chilling Generic Drug Competition. Governor Hogan Should Veto Legislation To Keep Generic Drugs Affordable For Maryland Statement by Chester “Chip” Davis, Jr., President and CEO of the Association for Accessible Medicines Read the full article  ... Read more

19

Apr 2017

Aurobindo USA welcomes Senior VP of Commercial Operations

Aurobindo USA is proud to announce and welcome Paul Krauthauser as the company’s Senior Vice President of Commercial Operations reporting to Bob Cunard, Chief Executive Officer. Paul will be responsible for the retail generic business. He has more than 20 years of experience in US Pharmaceutical Sales including but not limited to demand planning, contracting... Read more

04

Apr 2017

President Donald Trump’s nomination of Dr. Scott Gottlieb to lead the Food and Drug Administration signals he is serious about increasing access to safe, effective and…

(March 11, 2017) WASHINGTON, DC  – “President Donald Trump’s nomination of Dr. Scott Gottlieb to lead the Food and Drug Administration signals he is serious about increasing access to safe, effective and affordable medicines for Americans while taking a market based, competitive approach towards lowering drug costs. Dr. Gottlieb is one of the most formidable... Read more